Biochemical and Biophysical Research Communications
Mini ReviewCorticotropin-releasing factor family and its receptors: Tumor therapeutic targets?
Section snippets
Possible role of CRFR1 in tumor
There are many documents indicating that CRFR1 was expressed in tumor cells and UCN/CRF could inhibit tumor cell growth via CRFR1 [14], [15], [16], [17], [18], [19]. It was showed that human neuroblastoma SH-SY5Y cells mainly expressed CRFR1 which was functionally coupled with cAMP formation [14]. Graziani et al. reported that UCN/CRF inhibited the growth of adenocarcinoma ishikawa cells time- and concentration-dependently, and this effect was mediated by CRFR1 [15]. It was also reported that
Role of CRFR2 in tumor angiogenesis
Though there are few reports about CRFR2 and tumors, the role of CRFR2 in tumoral formation and angiogenesis is being more and more followed with interest. Florio et al. found that UCN-mRNA was significantly reduced in human endometrial carcinoma versus healthy controls, and UCN peptide was not found in neopalstic samples [12]. Though CRF/UCN were reported to inhibit endometrium carcinoma cells via CRFR1 [15], the authors did not exclude CRFR2 involvement in tumor procession [12]. These
Other beneficial effects of UCN in tumor chemotherapy
Currently, cancer therapy drugs are aiming to multiple mechanisms of the generation and development of cancers. The effects of UCN on these aspects are gradually recognized.
It is widely accepted that cytotoxic agents have many severe side effects as traditional cytotoxic agents against cancer, such as chemotherapy-induced nausea and vomiting (CINV), cardiotoxicity, nephrotoxicity, myelosuppression, etc. As well known, most chemotherapeutic agents can injure gastrointestinal tract mucosa, and
Conclusion
UCN and CRF can directly inhibit tumor cell growth via CRFR1. Moreover, they can be recognized as biological response modifiers in cancer therapy. UCN can inhibit tumor angiogenesis via CRFR2, may reduce side effects of cytotoxic agents and enhance the curative effects of chemotherapeutics. Furthermore, UCN might be a potential MDR reversal agent.
Acknowledgment
This work was supported by Key Project of Jiangsu Provincial Natural Scientific Fund (BK2006727).
References (40)
- et al.
Physiology, pharmacology, and therapeutic relevance of UCNs in mammals: ancient CRF paralogs
Front. Neuroendocrinol.
(2007) - et al.
Nibbling at CRF receptor control of feeding and gastrocolonic motility
Trends. Pharmacol. Sci.
(2003) - et al.
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype
Mol. Cell. Endocrin.
(2007) - et al.
Human Y-79 retinoblastoma cells express functional corticotropin-releasing hormone receptors
Brain Res.
(1992) - et al.
Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells
FEBS Lett.
(1998) - et al.
Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin
J. Invest. Dermatol.
(1999) - et al.
The hallmarks of cancer
Cell
(2000) - et al.
Urocortin reduces the viability of adult rat vascular smooth muscle cells via inhibiting L-type calcium channels
Peptide
(2005) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
Biochem. Pharmacol.
(1999)- et al.
Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway
J. Biol. Chem.
(2000)
Urocortin a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor
Nature
Characterization of corticotropin-releasing factor receptor subtypes
Ann. NY Acad. Sci.
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin
Science
Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse
J. Comp. Neurol.
UCN and corticotropin-releasing factor receptor expression in normal cycling human ovaries
J. Clin. Endocrinol. Metab.
Expression of UCN and corticotropin-releasing factor receptor subtypes in the human heart
J. Clin. Endocrinol. Metab.
Expression of CRF1 and CRF2 receptors in human cancers
J. Clin. Endocrinol. Metab.
Urocortin expression in human pituitary gland and pituitary adenoma
J. Clin. Endocrinol. Metab.
Expression of urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma
Prostate
UCN expression is downregulated in human endometrial carcinoma
J. Endocrinol.
Cited by (20)
Urocortin stimulates ERK1/2 phosphorylation and proliferation but reduces ATP production of MCF7 breast cancer cells
2022, Molecular and Cellular EndocrinologyCitation Excerpt :Peptides of the CRF-family are present in all major organs of higher vertebrates where they can exert local effects. After the discovery of UCNs and their receptors’ expression in various tumors, the possible role of this peptide as a tumor regulator has become the interest of several laboratories (Arcuri et al., 2002; Florio et al., 2006; Kaprara et al., 2010a, 2010b; Wang and Li, 2007). The effects of CRF on tumor cells depend on cell and tissue type, which in turn determines the expression of specific CRF receptor isoforms.
P7, a novel antagonist of corticotropin releasing factor receptor type 1 (CRFR1) screened from phage display library
2015, Biochemical and Biophysical Research CommunicationsCitation Excerpt :The peptide plays crucial roles in modulating the hypothalamic-pituitary-adrenal (HPA) axis activated by stressful stimuli, as well as behavioral, autonomic, endocrine, reproductive, cardiovascular, gastro-intestinal, metabolic and immune systemic functions, or homeostasis and viability of peripheral organs [2–5]. Moreover, CRF effects have also been found in tumorgenesis [6,7], mood disorders [8], neuroplasticity [9,10], skin stress response system [11], inflammation [12,13], addiction [14–16] and Alzheimer's disease [17]. CRF exerts its biological function via binding to its receptors (CRFR).
Differential Expression of Urocortin in Human Testicular Germ Cells in Course of Spermatogenesis: Role for Urocortin in Male Fertility?
2009, UrologyCitation Excerpt :Therefore, the cell cycle status-dependent expression of urocortin and its regulation in fetal and adult human testicular germ cells could be of oncologic relevance in testicular neoplasia. Because evidence is emerging that the urocortin/CRFR system is involved in neoplasia,8,28-30 future investigations in the testis will be of great interest. The results of the present study have demonstrated for the first time that human adult and fetal testes express urocortin.
Chapter 1 Recent Advances in Corticotropin-Releasing Factor Receptor Antagonists
2008, Annual Reports in Medicinal ChemistryCitation Excerpt :Recent findings in the above areas will be covered in this section. There have also been preliminary studies suggesting that CRF may play a role in other disease areas such as cardiac autonomic disorders [52], inflammatory disease [53], pain [54,55], cancer [56], and immune disorders [57]. These potential indications will not be discussed here.
An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma
2023, Journal of Cancer Research and Clinical Oncology